Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Midazolam
Accord Healthcare Ireland Ltd.
N05CD; N05CD08
Midazolam
1 milligram(s)/millilitre
Solution for injection/infusion
Product subject to prescription which may not be renewed (A)
Benzodiazepine derivatives; midazolam
Marketed
2009-03-06
NLH107700 var PSUSA July 23 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT MIDAZOLAM 1 MG/ML SOLUTION FOR INJECTION OR INFUSION MIDAZOLAM 5 MG/ML SOLUTION FOR INJECTION OR INFUSION midazolam Read all of this leaflet carefully before you are given this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET: 1. What midazolam is and what it is used for 2. What you need to know before you are given midazolam 3. How midazolam is given 4. Possible side effects 5. How to store midazolam 6. Contents of the pack and other information 1. WHAT MIDAZOLAM IS AND WHAT IT IS USED FOR Midazolam 1 mg/ml & 5 mg/ml Solution for Injection or Infusion contains Midazolam which belongs to a group of medicines known as benzodiazepines. It is a short acting medicine that is used to induce sedation (a very relaxed state of calm, drowsiness or sleep) and relieves anxiety and muscle tension. This medicine is used for: - Conscious sedation (an awake but very relaxed state of calm or drowsiness during a medical test or procedure) in adults and children - Sedation of adults and children, in intensive care units. - Anaesthesia in adults, used alone or with other medicines. - Premedication (medicine used to cause relaxation, calm and drowsiness before an anaesthetic) in adults and children. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN MIDAZOLAM YOU MUST NOT BE GIVEN MIDAZOLAM • If you are allergic (hypersensitive) to midazolam or any of the other ingredients of the medicine (listed in section 6) • You are allergic to other benzodiazepine medicines, such as diazepam or nitrazepam. You have severe breathin Read the complete document
Health Products Regulatory Authority 25 August 2023 CRN00DR33 Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Midazolam 1 mg/ml Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution for injection or infusion contains 1 mg of midazolam (as midazolam hydrochloride) Presentations 5 ml Amount of midazolam 5 mg Excipient: Contains 3.53 mg sodium (as sodium chloride) per ml of solution for injection or infusion. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for Injection or Infusion. Clear, colorless to pale yellow solution with a pH in the range of 2.9 - 3.7 and 270 mOsm/kg to 330 mOsm/kg osmolality. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Midazolam is a short acting sleep-inducing active substance that is indicated: _In adults:_ CONSCIOUS SEDATION before and during diagnostic or therapeutic procedures with or without local anaesthesia. ANAESTHESIA – Premedication before induction of anaesthesia – Induction of anaesthesia – As a sedative components in combined anaesthesia SEDATION IN INTENSIVE CARE UNITS _In children:_ CONSCIOUS SEDATION before and during diagnostic or therapeutic procedures with or without local anaesthesia. ANAESTHESIA – Premedication before induction of anaesthesia SEDATION IN INTENSIVE CARE UNITS 4.2 POSOLOGY AND METHOD OF ADMINISTRATION STANDARD DOSAGE Midazolam is a potent sedative agent that requires titration and slow administration. Titration is strongly recommended to safely obtain the desired level of sedation according to the clinical need, physical status, age and concomitant medication. In adults over 60 years, debilitated or chronically ill patients and paediatric patients, dose Health Products Regulatory Authority 25 August 2023 CRN00DR33 Page 2 of 16 should be determined with caution and risk factors related to each patient should be taken into account. Standard dosages are provided in Table 1 and additional details are provided in the Read the complete document